Therefore, we took advantage of the use of stiripentol, an antiepileptic drug approved by the FDA for the treatment of Dravet Syndrome, because it also potently inhibits both LDHA and LDHB activity (Sada et al, 2015). This evidence concerns the gene LDHA and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.